Direct from blood identification of bloodstream infections in newborns

直接从血液中鉴定新生儿血流感染

• 批准号: 10477151
• 负责人: Alon Singer
• 金额: $ 99.46万
• 依托单位: HELIXBIND, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10477151
• 关键词: Accounting; Address; Adopted; Adult; Affect; Antibiotics; Antimicrobial Resistance; Biological Assay; Birth; Blood; Blood Volume; Blood specimen; Budgets; Chicago; Childhood; Clinic; Clinical; Clinical Microbiology; Clinical Research; Clinical assessments; Communicable Diseases; DNA sequencing; Data; Detection; Development; Devices; Diagnosis; Diagnostic; Diagnostic Equipment; Diagnostic tests; Disease; Early Diagnosis; Ensure; Etiology; Evidence based treatment; Exhibits; Feedback; Hospitals; Hour; Infection; Intervention; Laboratories; Life; Live Birth; Medical center; Methods; Molecular; Morbidity - disease rate; Neonatal Mortality; Newborn Infant; Outcome; Patients; Pediatric Hospitals; Performance; Phase; Population; Positioning Attribute; Preparation; Process; Regulatory Pathway; Resistance; Risk; Sampling; Sensitivity and Specificity; Sepsis; Specificity; Stress; System; Technology; Temperature; Testing; Time; TimeLine; University Hospitals; Whole Blood; Work; accurate diagnosis; antimicrobial; assay development; base; cost; cross reactivity; design; diagnostic assay; diagnostic platform; diagnostic strategy; experience; in-vitro diagnostics; innovation; instrument; instrumentation; intrapartum; manufacturing scale-up; meetings; member; microbial; microbiome; mortality; neonatal sepsis; neonate; outcome prediction; pathogen; pathogenic bacteria; pathogenic fungus; patient population; performance tests; product development; programs; resistance gene; side effect; success; systemic inflammatory response

PROJECT SUMMARY Neonatal sepsis is a life-threatening disease that affects 2 out of every 1,000 live births in the US. Caused by an invasive bloodstream infection (BSI) occurring either at the time of birth or soon thereafter, the disease’s initial clinical manifestations are often non-specific, variable, at times subtle, and often common to signs of stress. Early diagnosis followed by appropriate antimicrobial intervention is a key predictor of outcomes. Selection of appropriate antimicrobials is limited by the current diagnostic process for detection and identification of BSIs which all rely on primary blood cultures. Cultures are slow, often requiring days to yield a result, and prone to false-negatives due to maternal antibiotics. In the absence of diagnostic confirmation, treatment is initiated upon suspicion of sepsis with broad spectrum antibiotics. Unfortunately, this strategy often misses the target and is associated with side effects, including damage to developing microbiomes. It is therefore critical to advance innovative diagnostic approaches which do not rely on culturing in order to facilitate accurate diagnosis and timely transition to evidence-based treatments. To address this unmet need, HelixBind developed RaPID/neo, a fully automated, sample-to-answer test for identifying BSIs directly from newborn blood within ~3 hours, without cultures. The test incorporates a broad test menu of 18 bacterial and fungal pathogens that make up the vast majority of neonatal sepsis cases. RaPID/neo is implemented on the RaPID (Resistance and Pathogen IDentification) platform, incorporating single-use test cassettes and a bench top Analyzer. RaPID/neo provides single CFUs/ml sensitivity across its test menu and is not confounded by polymicrobial infections nor prior antimicrobial treatment. In a preliminary clinical assessment, RaPID/neo demonstrated >92% sensitivity and 99% specificity across the assay. In this proposed Direct-to-Phase II project, HelixBind will build on its preliminary data to further product development by addressing analytical challenges associated with developing a test targeting this vulnerable patient population. We will review our findings and proposed studies for regulatory clearance with the FDA during a Pre-Submission process with the agency. Leveraging agency feedback, we will design an in-hospital study aimed at challenging our clinical studies plan in preparation for the pivotal trials for FDA clearance. To succeed in this endeavor, we have assembled an accomplished team with expertise in assay development, instrumentation, consumables manufacturing, clinical microbiology, and infectious disease as well as a successful track record of commercializing IVD platforms and assays. Together, we will build upon our preliminary work to complete product development, finalize a regulatory pathway, and challenge the system with an in-hospital study. Upon completion of this project, we will be well placed to initiate formal Analytical and Clinical studies for FDA clearance of RaPID/neo.

项目总结